Neuraxpharm, one of the leading European manufacturers of drugs for diseases and disorders of the central nervous system (CNS), has announced the purchase of part of Glenmark’s portfolio in Poland. At the same time, Neuraxpharm Polska will be headed by Jacek Sawicki.
Neuraxpharm expands its product portfolio for CNS
The acquisition covers a portfolio of 20 Glenmark products for the central nervous system. These are both Rx drugs and OTC products. The transaction includes such generic brands as Cital and Lamotrix and Revitanerw dietary supplement, used for regeneration and reconstruction of nerve cells.
The purchase of part of the Glenmark portfolio strengthens Neuraxpharm’s position on the Polish market. The company has been directly present in Poland since April 2019, when it opened a branch in Warsaw. Earlier, from 2014, products for the Polish market were delivered from the company’s German branch. The key point of the company’s development strategy is to enter the fast-growing markets in Europe. The goal of Neuraxpharm is to strengthen its position in Poland as a specialist company offering products for CNS disorders, both standard generic drugs and para-pharmaceuticals (including probiotics and nutraceuticals). Neuraxpharm specialises in products for the central nervous system, which account for over 85% of the company’s sales.
Jacek Sawicki appointed general manager of Neuraxpharm for Poland
As part of the transaction, the Glenmark CNS promotional team will join the marketing and sales department of Neuraxpharm Poland. Furthermore, Jacek Sawicki, current country manager of Glenmark Poland, will take over the position of general manager of Neuraxpharm for Poland. Currently, the Polish department of the company is subordinated to Olaf Krampe, who heads the Central European region in the company and is also the general manager for Germany.
Jacek Sawicki in his career was associated with UCB Pharma, Teva, Actavis and S-Lab. He has been associated with Glenmark Polska since October 2017.